Gluskin Sheff & Assoc Inc. purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) during the first quarter, Holdings Channel reports. The institutional investor purchased 6,803 shares of the biopharmaceutical company’s stock, valued at approximately $4,751,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Bailard Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $210,000. Kovitz Investment Group Partners LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $2,065,000. Steward Partners Investment Advisory LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.4% in the 1st quarter. Steward Partners Investment Advisory LLC now owns 3,756 shares of the biopharmaceutical company’s stock valued at $2,623,000 after acquiring an additional 53 shares in the last quarter. B. Metzler seel. Sohn & Co. AG increased its stake in shares of Regeneron Pharmaceuticals by 14.8% in the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 7,513 shares of the biopharmaceutical company’s stock valued at $5,248,000 after acquiring an additional 968 shares in the last quarter. Finally, Achmea Investment Management B.V. bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $17,405,000. Institutional investors and hedge funds own 84.92% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on REGN. Evercore ISI set a $635.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, June 20th. Barclays lifted their price objective on shares of Regeneron Pharmaceuticals from $735.00 to $815.00 and gave the company an “overweight” rating in a research note on Friday. Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $635.00 to $645.00 in a research note on Wednesday, July 20th. Morgan Stanley upgraded shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $625.00 to $851.00 in a research note on Friday. Finally, Cowen boosted their price target on shares of Regeneron Pharmaceuticals to $655.00 in a research note on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $741.58.
Insider Buying and Selling
Regeneron Pharmaceuticals Stock Performance
NASDAQ REGN opened at $710.74 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $538.01 and a 1 year high of $754.67. The company has a debt-to-equity ratio of 0.13, a current ratio of 5.12 and a quick ratio of 4.39. The firm has a market cap of $77.48 billion, a price-to-earnings ratio of 14.19, a PEG ratio of 2.52 and a beta of 0.29. The company has a fifty day moving average price of $607.57 and a 200-day moving average price of $636.33.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last posted its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.94 by ($0.17). The firm had revenue of $2.86 billion during the quarter, compared to the consensus estimate of $2.80 billion. Regeneron Pharmaceuticals had a return on equity of 36.17% and a net margin of 39.97%. The business’s revenue was down 44.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $27.97 EPS. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.97 EPS for the current fiscal year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
- Get a free copy of the StockNews.com research report on Regeneron Pharmaceuticals (REGN)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn’t Differentiate, But it’s Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.